Research Outcomes

Research Summary

Sr. No. PI, Co-PI and Project Title Funding Agency Investigators Grant Received in Rs. (lakhs) Duration (Yr.) Nat. / Inter./ DPU/Dept.
1. Prevalence of microalbuminuria as a marker of early nephropathy in obese non diabetic and non hypertensive patients with reference to adipokine levels ICMR PI: Dr. Varsha Bhatt, CI : Dr. Dr. S. A. Kanitkar Dr. M. Karandikar Total grant:19, 78,000/- Grant released: 1st 8,80,300/- 2nd 6,20,000/- 2019 2.5 Years National
2. Search for GAD 65 antibodies in discharged COVID-19 patients as predictive marker for Type 1 Diabetes. DPU PI: Dr. S. A. Kanitkar CI: Total grant:4,00,000/- 2021 2 Year DPU
3. A follow up study of Pulmonary sequelae in patients diagnosed with COVID-19 in a tertiary care center: DPU PI : Dr. Varsha Bhatt Dr. S. A. Kanitkar Dr. Aksahy Dhamne Total grant:4,00,000/- 2021 2 Year DPU
4. National Clinical Registry of COVID 19 ICMR PI: Dr. Sachin Shivnitwar Dr. Varsha Bhatt Dr. S. A. Kanitkar Total grant: 2021 1 Year DPU
5. Developing Bank of Human Induced Pluripotent Stem Cells for Drug Screening, Disease Modeling and Understanding Disease Biology NCCS and DST Dr. Bhumika Vaishnav (PI), Dr. A. L. Kakrani Total grant: 6,00,00,000/- 3 Years

List of PhD Students

Sr. No. Name of the faculty Title of the Research Topic Name of the Research Student Date of enrolment of the Research
1. Dr. A. L Kakrani Comprehensive Assement of Glycemia In Subject With Type 2 Diadetes Mellitus And Chronic Kidney (CKD) Dr. Vedavati Purandare 01-12-2016
2. Dr. A. L Kakrani Study of Prevalence of H. Pylori Infection and Endoscopic Evaluation of Patients with Symptoms of Dyspepsia. Dr. Prasad Bhate 15-02-2019

List of ICMR – STS Research projects sanctioned

Sr. No. Name of Student Name of Guide Topic Year Status
1. Pragati Maske Dr. Bhumika Vaishnav Study of Clinical Profile of urinary tract infection geriatric patient with type 2 DM 2014 Completed
2. Pragati Maske Dr A. A. Bamanikar Study Of Relationship Between Body Mass Index And Gastro-Oesophageal Reflux Disease 2015 Completed
3. Sanam Singh Dr Meenakshi Kalyan Ifect of passive somking as a risk facter for COPD in normal healthy women 2016 Completed
4. Vedita Kapoor Dr. Manasi Harale “Effect of Complication of Diabetes Mellitus on The Mental Health of a Patient”. 2017 Completed
5. Sakshi Duggal Dr. A. A. Bamanikar Risk Assessment for prevalence of OSA in Diabetic Patients on the baris of validated questionainesn 2018 Completed
6. Srishti Yadav Dr. Varsha Bhatt A Study of high sensitivity Creactive protein and carotid intsima media thikness levels, in pre-menopausal women exposed to seuond hand smoke 2018 Completed
7. Suraj Dinkar Barne Dr. Manasi Harale “A Comprehensive study of the association between Pulmonary Tuberculosis and Impaired Cardiopulmonary function in Patients under Treatment for Pulmonary Tuberculosis in a tertiary Hospital” 2019 Completed
8. Dr. Govid Shiddapur Sidhi Sanjay Raut Association of Serum Ferritin Level With Smoking And Lung Function In Chronic Obstructive Pilmonary Disorders (COPD) Patients. 2020 Ongoing
9. Dr. Bhumika Vaishnav Seherish Gangani Comparative Study of SpirometryParameters In Chronic Smokers With And Without Diabetes Mellitus 2020 Ongoing
10. Dr. Manasi Harale Virija Dharanikota Anti-TPO Antibody’s Association With Symptoms Of Hypothyroidism 2020 Ongoing

Clinical Trials

Sr. No. Name of Trial Company
Dr. A. L. Kakrani (Principal Investigator)
1 Primaquine SR vs. Conventional Primaquine in Patients with P. Vivax Malaria IPCA Mumbai
2 Non-inferiority study of 2 tetanus toxoid vaccines Biological Evans, Hyderabad
3 Safety of losartan-Metoprolol vs losartan- ramipril in HTN with Type 2DM IPCA Mumbai
4 Phase IV Clinical Study protocol of monovalent tetanus toxoid vaccine Biological E. ltd
5 Efficacy and safety of hydroxychloroquine in the treatment of type II diabetes mellitus IPCA Mumbai
6 A Randomized, double-blind, comparative, multicentre, phase II/III study of evaluate the immunogenicity and safety of three formulations (15ug without adjuvant and 3.75ug with adjuvant) of monovalent H1N1 influenza A (2009) virus vaccine in healthy adults Panacea Biotec ltd
7 A single centre open label phase -1 to evaluate the safety and reactogenicity of BE’s Inactivated JE vaccine in > 18 to < 49-year-old healthy adult male subjects Biological Evans ltd
8 A Randomized, double-blind, comparative, multicentre, phase II/III study of evaluate the immunogenicity and safety of three formulations (15ug without adjuvant and 3.75ug with adjuvant) of monovalent H1N1 influenza A (2009) virus vaccine in healthy adults Panacea Biotec ltd
Dr. A. L. Kakrani (Co-Investigator)
9 A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300mg of intravenous zanamivir twice daily compared to 75mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza GSK Pharmaceuticals Ltd.
10 Immunogenicity & safety of a tetravalent dengue vaccine in healthy adult subjects aged 18-45 yrs in India Sanofi Pasteur
11 An open-Label, Randomized, phase I study in Healthy Male adults to evaluate the safety of Measles Vaccine (Dry Powder) Administered by Two Devices Serum Institute of India Ltd.
12 A Phase 3, multi-center, open-label study of evaluate immunogenicity and safety of Novartis Meningococcal ACWY conjugate vaccine (Men ACWY- CRM) in healthy subjects from 2-75 years of age in India Novartis vaccines and Diagnostics
13 Comparative Evaluation of efficacy and safety of Telmisartan plus chlorthalidone combination with Telmisartan plus Hydrochlorthiazide combination in patients with mild to moderate essesntial Hypertension Dr.S.K.Sharma IPCA Mumbai
14 Evaluation of Efficacy and Safety of Hydroxychloroquine Sulfate as an Adjunct to Diet and Exercise to Improve Glycemic Control in Type 2 Diabetes Patients Uncontrolled on Sulfonylurea + Metformin Combination Dr. A.L.Kakrani IPCA ,Mumbai

PROJECTS

Ongoing Projects:
Sr. No. Name of Trial Company Sr. No. Name of Trial Company
1. “A phase 2/3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1TM adjuvant] in Indian adults” ICMR SERUM Institute of India Dr. Varsha Bhatt, Total grant:36,48,140/- started in March 2021
2. GINOVA Dr. Prakash Shende 2021

Completed Projects:
Sr. No. PI, Co-PI and Project Title Funding Agency Grant Received (Rs. Lakhs) Duration Nat. / Inter./ DPU/Deptt
1 Dr. A. L. Kakrani
Study of Nonalcoholic Fatty Liver Disease in overweight population		 DPU Pune
Completed 2014		 12.00 3 Years DPU
2 Dr. A. L. Kakrani
Dengue infection MODS – multi centric study (DIMODS-IPRI)		 IPRI-ISCCM Pune
2015		 0.20 2 Years IPRI-ISCCM Pune
3 Dr. S. A. Kanitkar
Study of metabolic syndrome in medical students		 DPU Pune
Completed 2014		 0.50 3 Years DPU
4 Evaluation of Safety and Efficacy of Hydroxychloroquine Sulfate as an Adjunct to Diet and Exercise to Improve Glycemic Control in Type 2 Diabetes Patients Uncontrolled on Sulfonylurea + Metformin Combination Dr. A. L. Kakrani 0.78 2 Years -
5 Tuberculosis and Diabetes Mellitus: Longer-Term Outcomes and Interactions Dr. A. L. Kakrani
Amount sent to PI in Dept. of Pulmonology		 - - -
Sr. No Name of the Project Name of the Principal Investigator/ Co Investigator Name of the sponsor Research grant Year of starting Status
1 “Prevalence of microalbuminuria as a marker of early nephropathy in obese non-DM and non-hypertensive patients with reference to adipokine levels”. Principal Investgator Dr. Varsha Bhatt Co- Investigator Dr. A. L. Kakrani Dr Mahesh Krandikar
Dr. Shubhangi A. Kanitkar 		ICMR ₹ 15,09,965.00 2019 Completed
2 “A phase 2/3, observer-blind,
randomized, controlled study to determine the
safety and immunogenicity
of COVOVAX [SARS-CoV-2
recombinant spike protein
nanoparticle vaccine
(SARS-CoV-2 rS)
with Matrix-M1™
adjuvant] in Indian
adults”. 		Principal Investgator Dr. Varsha Bhatt Co- Investigator Dr. A. L. Kakrani Dr Srikanth Tripathy Dr. Akshay A. Dhamne
Dr. Shubhangi A. Kanitkar
Dr. Abhijit V. Tilak
Dr. Parag J. Ratnakar
Dr Shahzad Mirza
Dr Prachi Athavale
Dr Mandakini Bhowmick Regulatory Manager: Savita Mahajan 		 Serum Institute of
India Private
Limited (SIPL) and
ICMR ( Co- sponsor) CRO- PPD pharmaceuticals 		₹ 39,87,469.00 Mar 2021 Completed
3 Randomized, Phase I/II, Placebo-controlled, Dose-Ranging, study to evaluate the Safety, Tolerability and Immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy adult subjects Principal Investgator Dr. Prakash Shende Co- Investigator Dr. A. L. Kakrani Dr Srikanth Tripathy
Dr. Shubhangi A. Kanitkar
Dr Shahzad Mirza Regulatory Manager: Savita Mahajan 		Gennova Biopharmaceutic
als Limited CRO-DiagnoSearch Life Sciences
Pvt. Ltd. 		₹ 81,716.00 May-21 Completed
4 A Prospective,
Multicentre,Randomized, Active-controlled, Observer-blind, Phase II study seamlessly followed by a Phase
III study to evaluate the Safety, Tolerability and Immunogenicity of the
candidate HGCO19 (COVID-19 vaccine)
in healthy subjects 		Principal Investgator Dr. Prakash Shende Co- Investigator Dr. A. L. Kakrani Dr Srikanth Tripathy
Dr. Shubhangi A. Kanitkar
Dr Shahzad Mirza Regulatory Manager: Savita Mahajan 		Gennova Biopharmaceutic
als Limited CRO-DiagnoSearch Life Sciences
Pvt. Ltd. 		₹ 32,50,633.00  Sept 2021 Completed

Sr. No

Name of the Project

Name of the Principal Investigator/ Co Investigator

Name of the sponsor

Research grant

Year of starting

Status

1

Search for GAD 65 antibodies in discharged covid - 19 patients as predictive marker for type 1 diabetes

Dr. Shubhangi Kanitkar

DPU Funded

₹ 3,00,000.00

2020

ongoing

2

a follow up study of Pulmonary seqeiae in patients diagnosed with covid -19 in a tertiary care center

Dr. Shubhangi Kanitkar

DPU Funded

₹ 4,00,000.00

2020

ongoing

3

ICMR-WHO
Solidarity Trial Plus: -
“An international
randomised trial of
additional treatments
for COVID-19 in
hospitalised patients

Principal Investgator Dr. Shubhangi Kanitkar Co- Investigator Dr. A. L. Kakrani Dr Srikanth Tripathy
Dr. Varsha Bhatt
Dr. Thomas Ben Dr Narendran Sairam Regulatory Manager: Savita Mahajan

ICMR and WHO

₹ 4,57,269.00

 OCT 2021

Completed

4

“National Clinical Registry for COVID-19”

Principal Investgator Dr. Dr. Sachin K. Shivnitwar Co- Investigator Dr. Shubhangi Kanitkar

ICMR

₹ 19,39,980.00

2021

Completed

5

RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY)

Principal Investgator Dr. Shubhangi Kanitkar Co- Investigator Dr. A. L. Kakrani Dr Srikanth Tripathy
Dr. Varsha Bhatt Regulatory Manager: Savita Mahajan

University of Oxford India Co-ordinator- ICMR

₹ 2,97,997.00

 Jul 2022

Completed

6

A Prospective, Multi-centre, Open-labelled, Randomized, Phase II study seamlessly followed by a Phase III study to evaluate the Safety, Tolerability and Immunogenicity of GEMCOVAC-
OM as a booster in Subjects 18 years of age and older

Principal Investgator Dr. Vikram Vikhe Co- Investigator Dr. A. L. Kakrani Dr Srikanth Tripathy
Dr. Shubhangi A. Kanitkar
Dr. Shahzad Mirza
Dr. Prachi Athavale Regulatory Manager: Savita Mahajan

Gennova Biopharmaceutic
als Limited CRO-JSS Medical Research Asia Pacific Pvt.Ltd.

₹ 62,94,350.00

Nov-22

Completed

7

Profiling of circulating long non coding RNA’s underlying the Metformin treatment in patients with type 2 diabetes. 

In collaboration with Biotechnology college Dr.Shubhangi Kanitkar

DPU

 Biotechnology college

2022

Completed

8

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-
Controlled Study to Evaluate the Efficacy, Immunogenicity and
Safety of Single dose of “DengiAll”, a Live Attenuated
Recombinant, Lyophilized Tetravalent Dengue Vaccine (TDV) in
Healthy Indian Adults

Principal Investgator Dr. Shubhangi Kanitkar Co- Investigator Dr. A. L. Kakrani Dr Srikanth Tripathy Regulatory Manager: Savita Mahajan

Sponsor:- PANACEA BIOTEC LIMITED Co-Sponsor:- Indian Council of Medical Research (ICMR)

₹ 86,68,420

2023

Ongoing

9

Hospital based study to understand the role of host and viral factors in predicting severe dengue and the cost of illness of dengue : A pilot Study

ICMR Dr. Shubhangi Kanitkar Dr. Manaswini

ICMR

₹ 25,00,000/-

2023

Completed

10

Factors associated with sudden deaths among adults aged 18–45 years, India: Multicentric matched case-control study.'

 Dr. Sachin Shivnitwar Dr. Shubhangi Kanitkar

ICMR

₹ 1,50,000/-

2023

Completed

11

Study documents- Effect of COVID-19 vaccine on thrombotic events

 Dr. Sachin Shivnitwar Dr. Shubhangi Kanitkar

ICMR - National Institute of Epidemiology

₹ 1,68,700

2023

Completed 

12

Global action in healthcare network (GAZHN) antimicrobial resistance in India enhaced infection control and prevention driven by targeted surveillance. To implement a form of enhance infection control and prevention (IPC) guided by active and passive surveillance for cabapenem and colistin resistant Gram- Negative orgnaisms.

Dr.Shubhangi Kanitkar

ICMR - National Institute of Epidemiology

₹. 4 crore

2022

ongoing

13

HATHI Trial Hybrid Trial for Alcohol in TB and HIV in India CTRI Reg.No.2020/03/024141

Dr. A.L.Kakrani Dr. Shubhangi Kanitkar Dr. Bhumika Vaishnav

National Institute on Alcohol Abuse and alcoholism (NIAAA) A Devision of NIH, USA in collaboration with JHU

$192415

2019

ongoing

14

ENACTING Unmet needs for health and social care among older people in India and Sweden

Dr. Shubhangi Kanitkar Dr. Sarika Chaturvedi

Financial Assistant is provided by Swedish Foundation for international cooperation in research and higher education (STINT) in collaboration with Gothenburg University Sweden and DPU Pune

149999 SEK Rs.1210633.39

2023

not yet start

15

STUDY OF SMART COP SCORE IN COMMUNITY ACQUIRED PNEUMONIA AND PREDICTING NEED OF INTENSIVE RESPIRATORY AND VASOPRESSOR SUPPORT

Dr. ROOPAL PORWAL

Dr. G.S. Shiddapur

Selected in ICMR

Rs. 100000/-

Not yet received

2025

Ongoing

16

STUDY OF CLINICAL PROFILE AND COMPLICATIONS OF PATIENTS WITH TYPE 1 AND TYPE 2 RESPIRATORY FAILURE ADMITTED TO TERTIARY CARE CENTRE

DR. PRARTHANA PATEL

Dr. V.B Vikhe

Selected in ICMR

Rs. 100000/-

Not yet received

2025

Ongoing